🇺🇸 FDA
Pipeline program

Sativex and rifampicin

GWCP0602

Phase 1 small_molecule completed

Quick answer

Sativex and rifampicin for Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4 is a Phase 1 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Jazz Pharmaceuticals plc
Indication
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials